---
title: Slow Parkinson progression with glucoraphanin
nct_id: NCT07360977
phase: NA
status: RECRUITING
sponsor: IRCCS Centro Neurolesi Bonino Pulejo
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07360977"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07360977"
last_fetched: "2026-05-10T14:03:08.744Z"
source: "Parkinson's Pathways (curated)"
---
# Slow Parkinson progression with glucoraphanin

**Goal (in five words):** Slow Parkinson progression with glucoraphanin

**Official Title:** A Composition Comprising Glucoraphanin, Myrosinase and a Buffered Solution for Use in the Treatment of Neurodegenerative Diseases

**Trial ID:** [NCT07360977](https://clinicaltrials.gov/study/NCT07360977)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** IRCCS Centro Neurolesi Bonino Pulejo
- **Target Enrollment:** 300 participants
- **Start Date:** 2026-01
- **Completion Date:** 2026-05-19
- **Conditions:** PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting, Pediatric Patients Affected by Neuromuscolar and Degenerative Diseases
- **Interventions:** bioactivated GRA for adult patients, bioactivated GRA for pediatric patients
- **Intervention Types:** DRUG

## Summary For Families

The goal is to reduce nerve cell damage from oxidative stress and inflammation that can drive Parkinson's progression, with the hope of protecting neurons and slowing decline. The approach gives bioactivated GRA, a mix of glucoraphanin plus myrosinase in a buffered solution that converts to sulforaphane in the body and activates the Nrf2 antioxidant and detox pathways, and it is intended to be used alongside stable anti-parkinsonian meds rather than replace levodopa. Enrollment includes several groups, notably people with Parkinson's aged 45 to 75 meeting UK Brain Bank criteria who have had stable anti-parkinsonian treatment for at least three months, adults with relapsing-remitting MS, and clinically stable pediatric patients aged 1 to 10 who weigh 5 to 30 kg. People with MRI contraindications, significant cognitive impairment (MMSE <24), major comorbidities, pregnancy, or recent changes in treatments are excluded.

## Eligibility

- **Minimum age:** 1 Year
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

Inclusion Criteria for PD:

* Male or female patients aged between 45-75 years old.
* Clinical diagnosis of PD according to UK Brain Bank Criteria.
* 3 months of clinical stability before study enrolment.
* Anti-parkinsonian medication is fixed for at least 3 months prior to study entry.

Inclusion Criteria for MS:

* Male or female patients 18 years old or older.
* Diagnosis of RR-MS according to McDonald criteria.
* Expanded Disability Status Scale(EDSS) lower or equal to 5.5.
* Stable disease for at least 30 days prior to study entry.
* Stable disease-modifying therapy for at least 3 months prior to study entry.

Common inclusion criteria for MS and PD:

* No changes in drug treatment during 6 months-study treatment.
* Patients understand and comply with the study procedure and are able to complete tests and examinations required by the project.
* Written informed consent.

Inclusion criteria for pediatric patients:

* Eligible patients are those clinically stable;
* Age range from 1 to 10, between 5 and 30 kg.
* Patients not involved in other clinical trials.

Exclusion Criteria:

Exclusion criteria for PD and MS:

* Absolute contraindications to Magnetic Resonance Imaging (MRI).
* Concomitant neurological disease or severe co-morbidities able to influence outcomes such as spinal injury, cancer, dementia, or other central nervous system diseases such as stroke, epilepsy or psychiatric disorders;
* Total score of Mini-Mental State Examination (MMSE)\<24.
* Participating in other clinical trials.
* Pregnant/lactating.
```

## Locations (1)

- IRCCS Centro Neurolesi Bonino Pulejo, Messina, Italy _(38.1939, 15.5526)_

## Central Contacts

- Emanuela Mazzon — (CONTACT) — 09060128163 — emanuela.mazzon@irccsme.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT07360977*  
*HTML version: https://parkinsonspathways.com/trial/NCT07360977*  
*Source data: https://clinicaltrials.gov/study/NCT07360977*